Please assess the completion status of the following clinical trial:

Trial Title: Comparative Effect of Nebivolol vs. Metoprolol on Insulin Sensitivity and Fibrinolytic Balance in Metabolic Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Ambulatory subjects, 18 to 70 years of age, inclusive~2. For female subjects, the following conditions must be met:~   * postmenopausal status for at least 1 year, or~  * status-post surgical sterilization, or~  * if of childbearing potential, utilization of adequate birth control and willingness to undergo urine beta-hcg testing prior to drug treatment and on every study day~3. Metabolic syndrome as defined by 3 or more of the following:~   * Fasting plasma glucose of at least 100 mg/dL (5.5 mmol/L)~  * Serum triglycerides of at least 150 mg/dL (1.7 mmol/L)~  * Serum HDL cholesterol less than 40 mg/dL (1.04 mmol/L) in men and 50 mg/dL in women~  * Blood pressure of at least 130/85 mmHg~  * Waist girth of more than 102 cm in men or 88 cm in women~Exclusion Criteria:~Subjects presenting with any of the following will not be included in the study:~1. Diabetes type 1 or type 2, as defined by a fasting glucose of 126 mg/dL or greater or the use of anti-diabetic medication~2. Use of hormone replacement therapy~3. Change in statin therapy within the last 6 months~4. In hypertensive subjects, a seated systolic blood pressure greater than 179 mmHg or a seated diastolic blood pressure greater than 110 mmHg~5. Pregnancy~6. Breast-feeding~7. Cardiovascular disease such as myocardial infarction within 6 months prior to enrollment, presence of angina pectoris, significant arrhythmia, congestive heart failure (LV hypertrophy acceptable), deep vein thrombosis, pulmonary embolism, second- or third-degree heart block, mitral valve stenosis, aortic stenosis or hypertrophic cardiomyopathy~8. Treatment with anticoagulants~9. History of serious neurologic disease such as cerebral hemorrhage, stroke, or transient ischemic attack~10. History or presence of immunological or hematological disorders~11. Diagnosis of asthma~12. Clinically significant gastrointestinal impairment that could interfere with drug absorption~13. Impaired hepatic function (aspartate amino transaminase \[AST\] and/or alanine amino transaminase \[ALT\] \>2.0 x upper limit of normal range)~14. Impaired renal function (serum creatinine \>1.5 mg/dl)~15. Hematocrit \<35%~16. Any underlying or acute disease requiring regular medication which could possibly pose a threat to the subject or make implementation of the protocol or interpretation of the study results difficult~17. Treatment with chronic systemic glucocorticoid therapy (more than 7 consecutive days in 1 month)~18. Treatment with lithium salts~19. History of alcohol or drug abuse~20. Treatment with any investigational drug in the 1 month preceding the study~21. Mental conditions rendering the subject unable to understand the nature, scope and possible consequences of the study~22. Inability to comply with the protocol, e.g. uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study~23. Inability to swallow capsules

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Nebivolol (Type: ACTIVE_COMPARATOR): Nebivolol 5mg by mouth daily for 12 weeks.
- Metoprolol (Type: ACTIVE_COMPARATOR): Metoprolol ER 100mg by mouth daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).